ROGER CHAMMAS

(Fonte: Lattes)
Índice h a partir de 2011
27
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Mostrar mais
Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2021 ×

Resultados de Busca

Agora exibindo 1 - 10 de 24
  • article 17 Citação(ões) na Scopus
    The International Society of RNA Nanotechnology and Nanomedicine (ISRNN): The Present and Future of the Burgeoning Field
    (2021) CHANDLER, Morgan; JOHNSON, Brittany; KHISAMUTDINOV, Emil; DOBROVOLSKAIA, Marina A.; SZTUBA-SOLINSKA, Joanna; SALEM, Aliasger K.; BREYNE, Koen; CHAMMAS, Roger; WALTER, Nils G.; CONTRERAS, Lydia M.; GUO, Peixuan; AFONIN, Kirill A.
    The International Society of RNA Nanotechnology and Nanomedicine (ISRNN) hosts an annual meeting series focused on presenting the latest research achievements involving RNA-based therapeutics and strategies, aiming to expand their current biomedical applications while overcoming the remaining challenges of the burgeoning field of RNA nanotechnology. The most recent online meeting hosted a series of engaging talks and discussions from an international cohort of leading nanotechnologists that focused on RNA modifications and modulation, dynamic RNA structures, overcoming delivery limitations using a variety of innovative platforms and approaches, and addressing the newly explored potential for immunomodulation with programmable nucleic acid nanoparticles. In this Nano Focus, we summarize the main discussion points, conclusions, and future directions identified during this two-day webinar as well as more recent advances to highlight and to accelerate this exciting field.
  • article 12 Citação(ões) na Scopus
    Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis
    (2021) BHATT, Darshak K.; CHAMMAS, Roger; DAEMEN, Toos
    Resistance to therapy is a frequently observed phenomenon in the treatment of cancer, and as with other cancer therapeutics, therapies based on oncolytic viruses also face the challenges of resistance, such as humoral and cellular antiviral responses, and tumor-associated interferon-mediated resistance. In order to identify additional mechanisms of resistance that may contribute to therapeutic failure, we developed a systematic search strategy for studies published in PubMed. We analyzed 6143 articles on oncolytic virotherapy and found that approximately 8% of these articles use resistance terms in the abstract and/or title. Of these 439 articles, 87 were original research. Most of the findings reported pertain to resistance mediated by tumor-cell-dependent interferon signaling. Yet, mechanisms such as epigenetic modifications, hypoxia-mediated inhibition, APOBEC-mediated resistance, virus entry barriers, and spatiotemporal restriction to viral spread, although not frequently assessed, were demonstrated to play a major role in resistance. Similarly, our results suggest that the stromal compartment consisting of, but not limited to, myeloid cells, fibroblasts, and epithelial cells requires more study in relation to therapy resistance using oncolytic viruses. Thus, our findings emphasize the need to assess the stromal compartment and to identify novel mechanisms that play an important role in conferring resistance to oncolytic virotherapy.
  • article 9 Citação(ões) na Scopus
    Exercise Training Preserves Myocardial Strain and Improves Exercise Tolerance in Doxorubicin-Induced Cardiotoxicity
    (2021) GOMES-SANTOS, Igor L.; JORDAO, Camila P.; PASSOS, Clevia S.; BRUM, Patricia C.; OLIVEIRA, Edilamar M.; CHAMMAS, Roger; CAMARGO, Anamaria A.; NEGRAO, Carlos E.
    Doxorubicin causes cardiotoxicity and exercise intolerance. Pre-conditioning exercise training seems to prevent doxorubicin-induced cardiac damage. However, the effectiveness of the cardioprotective effects of exercise training concomitantly with doxorubicin treatment remains largely unknown. To determine whether low-to-moderate intensity aerobic exercise training during doxorubicin treatment would prevent cardiotoxicity and exercise intolerance, we performed exercise training concomitantly with chronic doxorubicin treatment in mice. Ventricular structure and function were accessed by echocardiography, exercise tolerance by maximal exercise test, and cardiac biology by histological and molecular techniques. Doxorubicin-induced cardiotoxicity, evidenced by impaired ventricular function, cardiac atrophy, and fibrosis. Exercise training did not preserve left ventricular ejection fraction or reduced fibrosis. However, exercise training preserved myocardial circumferential strain alleviated cardiac atrophy and restored cardiomyocyte cross-sectional area. On the other hand, exercise training exacerbated doxorubicin-induced body wasting without affecting survival. Finally, exercise training blunted doxorubicin-induced exercise intolerance. Exercise training performed during doxorubicin-based chemotherapy can be a valuable approach to attenuate cardiotoxicity.
  • article 6 Citação(ões) na Scopus
    Tumor-Derived Extracellular Vesicles: Modulation of Cellular Functional Dynamics in Tumor Microenvironment and Its Clinical Implications
    (2021) SANTOS, Nathalia Leal; BUSTOS, Silvina Odete; BHATT, Darshak; CHAMMAS, Roger; ANDRADE, Luciana Nogueira de Sousa
    Cancer can be described as a dynamic disease formed by malignant and stromal cells. The cellular interaction between these components in the tumor microenvironment (TME) dictates the development of the disease and can be mediated by extracellular vesicles secreted by tumor cells (TEVs). In this review, we summarize emerging findings about how TEVs modify important aspects of the disease like continuous tumor growth, induction of angiogenesis and metastasis establishment. We also discuss how these nanostructures can educate the immune infiltrating cells to generate an immunosuppressive environment that favors tumor progression. Furthermore, we offer our perspective on the path TEVs interfere in cancer treatment response and promote tumor recurrence, highlighting the need to understand the underlying mechanisms controlling TEVs secretion and cargo sorting. In addition, we discuss the clinical potential of TEVs as markers of cell state transitions including the acquisition of a treatment-resistant phenotype, and their potential as therapeutic targets for interventions such as the use of extracellular vesicle (EV) inhibitors to block their pro-tumoral activities. Some of the technical challenges for TEVs research and clinical use are also presented.
  • bookPart
    Princípios e classificações da terapia antineoplásica
    (2021) WATARAI, Gabriel Yoshiyuki; CHAMMAS, Roger
  • bookPart
    Agentes alquilantes e compostos relacionados
    (2021) MARTA, Guilherme Nader; CHAMMAS, Roger
  • article 8 Citação(ões) na Scopus
    Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk
    (2021) LU, Ye; GENTILUOMO, Manuel; MACAUDA, Angelica; GIOFFREDA, Domenica; GAZOULI, Maria; PETRONE, Maria C.; KELEMEN, Dezso; GINOCCHI, Laura; MORELLI, Luca; PAPIRIS, Konstantinos; GREENHALF, William; IZBICKI, Jakob R.; KIUDELIS, Vytautas; MOHELNIKOVA-DUCHONOVA, Beatrice; BUENO-DE-MESQUITA, Bas; VODICKA, Pavel; BRENNER, Hermann; DIENER, Markus K.; PEZZILLI, Raffaele; IVANAUSKAS, Audrius; SALVIA, Roberto; SZENTESI, Andrea; AOKI, Mateus Nobrega; NEMETH, Balazs C.; SPERTI, Cosimo; JAMROZIAK, Krzysztof; CHAMMAS, Roger; OLIVERIUS, Martin; ARCHIBUGI, Livia; ERMINI, Stefano; NOVAK, Janos; KUPCINSKAS, Juozas; STROUHAL, Ondrej; SOUCEK, Pavel; CAVESTRO, Giulia M.; MILANETTO, Anna C.; VANELLA, Giuseppe; NEOPTOLEMOS, John P.; THEODOROPOULOS, George E.; LAARHOVEN, Hanneke W. M. van; MAMBRINI, Andrea; MOZ, Stefania; KALA, Zdenek; LOVECEK, Martin; BASSO, Daniela; UZUNOGLU, Faik G.; HACKERT, Thilo; TESTONI, Sabrina G. G.; HLAVAC, Viktor; ANDRIULLI, Angelo; LUCCHESI, Maurizio; TAVANO, Francesca; CARRARA, Silvia; HEGYI, Peter; ARCIDIACONO, Paolo G.; BUSCH, Olivier R.; LAWLOR, Rita T.; PUZZONO, Marta; BOGGI, Ugo; GUO, Feng; MALECKA-PANAS, Ewa; CAPURSO, Gabriele; LANDI, Stefano; TALAR-WOJNAROWSKA, Renata; STROBEL, Oliver; GAO, Xin; VASHIST, Yogesh; CAMPA, Daniele; CANZIAN, Federico
    Although 21 pancreatic cancer susceptibility loci have been identified in individuals of European ancestry through genome-wide association studies (GWASs), much of the heritability of pancreatic cancer risk remains unidentified. A recessive genetic model could be a powerful tool for identifying additional risk variants. To discover recessively inherited pancreatic cancer risk loci, we performed a re-analysis of the largest pancreatic cancer GWAS, the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4), including 8,769 cases and 7,055 controls of European ancestry. Six single nucleotide polymorphisms (SNPs) showed associations with pancreatic cancer risk according to a recessive model of inheritance. We replicated these variants in 3,212 cases and 3,470 controls collected from the PANcreatic Disease ReseArch (PANDoRA) consortium. The results of the meta-analyses confirmed that rs4626538 (7q32.2), rs7008921 (8p23.2) and rs147904962 (17q21.31) showed specific recessive effects (p<10(-5)) compared with the additive effects (p>10(-3)), although none of the six SNPs reached the conventional threshold for genome-wide significance (p < 5x10(-8)). Additional bioinformatic analysis explored the functional annotations of the SNPs and indicated a possible relationship between rs36018702 and expression of the BCL2L11 and BUB1 genes, which are known to be involved in pancreatic biology. Our findings, while not conclusive, indicate the importance of considering non-additive genetic models when performing GWAS analysis. The SNPs associated with pancreatic cancer in this study could be used for further meta-analysis for recessive association of SNPs and pancreatic cancer risk and might be a useful addiction to improve the performance of polygenic risk scores.
  • article 1 Citação(ões) na Scopus
    Science, Technology and Innovation-oriented health centers, a COVID-19 legacy
    (2021) SILVA, RENAN G.L. DA; NOVAES, HILLEGONDA M.D.; CHAMMAS, ROGER
  • conferenceObject
    Radioactive and near-infrared fluorescence in vivo imaging of Non-Hodgkin Lymphoma using 99mTc/Cy7-Fab(Bevacizumab)
    (2021) CAMACHO, X.; PERRONI, C.; CARNEIRO, C.; JUNQUEIRA, M.; FARIA, D.; GARCIA, M.; FERNANDEZ, M.; BUCHPIGUEL, C.; CERECETTO, H.; CHAMMAS, R.; RIVA, E.; CABRAL, P.; GAMBINI, J.
  • article 7 Citação(ões) na Scopus
    Associations between initiating antihypertensive regimens on stage I-III colorectal cancer outcomes: A Medicare SEER cohort analysis
    (2021) BALKRISHNAN, Rajesh; DESAI, Raj P.; NARAYAN, Aditya; CAMACHO, Fabian T.; FLAUSINO, Lucas E.; CHAMMAS, Roger
    Purpose Colorectal cancer (CRC) diagnosis is associated with high mortality in the United States and thus warrants the study of novel treatment approaches. Vascular changes are well observed in cancers and evidence indicates that antihypertensive (AH) medications may interfere with both tumor vasculature and in recruiting immune cells to the tumor microenvironment based on preclinical models. Extant literature also shows that AH medications are correlated with improved survival in some forms of cancer. Thus, this study sought to explore the impact of AH therapies on CRC outcomes. Patients and Methods This study was a non-interventional, retrospective analysis of patients aged 65 years and older with CRC diagnosed from January 1, 2007 to December 31st, 2012 in the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database. The association between AH drug utilization on AJCC stage I-III CRC mortality rates in patients who underwent treatment for cancer was examined using Cox proportional hazards models. Results The study cohort consisted of 13,982 patients diagnosed with CRC. Adjusted Cox proportional hazards regression showed that among these patients, the use of AH drug was associated with decreased cancer-specific mortality (HR: 0.79, 95% CI: 0.75-0.83). Specifically, ACE inhibitors (hazard ratio [HR]: 0.84, 95% CI: 0.80-0.87), beta-blockers (HR: 0.87, 95% CI: 0.84-0.91), and thiazide diuretics (HR: 0.83, 95% CI: 0.80-0.87) were found to be associated with decreased mortality. An association was also found between adherence to AH therapy and decreased cancer-specific mortality (HR: 0.94, 95% CI: 0.90-0.98). Conclusion Further research needs to be performed, but AH medications may present a promising, low-cost pathway to supporting CRC treatment for stage I-III cancers.